Skip to main content
. 2007 Feb 27;105(Suppl 1):19–29. doi: 10.1007/s10549-007-9527-6

Table 2.

Objective response rate in different patient subgroups [57]

Subgroup Letrozole Tamoxifen
Dominant disease site: soft tissue n 113 115
ORR 50% 34%
Dominant disease site: bone n 145 131
ORR 23% 15%
Dominant disease site: viscera n 195 208
ORR 28% 17%
Patients who had n 84 83
    received prior ORR 26% 8%
    antiestrogen Odds ratio (95% CI)a 3.85 (1.50, 9.60)
HR-positive n 294 305
ORR 33% 22%
Odds ratio (95% CI)a 1.78 (1.20, 2.60)
HR-unknown n 159 149
ORR 30% 20%
Odds ratio (95% CI)a 1.79 (1.10, 3.00)

ORR, objective response rate; CI, confidence interval; HR, hormone receptor

aOdds ratios >1.0 indicate superiority for letrozole relative to tamoxifen